| Product Unit Size | Cost | Quantity | Stock |
|---|
Palomid 529 inhibits mTORC1/2 and exhibits anticancer chemotherapeutic and anti-angiogenic activities. Palomid 529 is currently in clinical trials as a potential treatment for macular degeneration. In mice with BRCA-1-deficient breast cancer tumors, palomid 529 inhibits tumor growth. Palomid 529 also inhibits angiogenesis and vascular permeability in cellular models. Additionally, palomid 529 indirectly inhibits downstream Akt signaling.
| Cas No. | 914913-88-5 |
|---|---|
| Purity | ≥98% |
| Formula | C24H22O6 |
| Formula Wt. | 406.43 |
| IUPAC Name | 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one |
| Synonym | P529 |
| Solubility | DMSO 81 mg/mL (199.29 mM) Water Insoluble Ethanol Insoluble |
| Appearance | White Crystal Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
Dalal M, Jacobs-El N, Nicholson B, et al. Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013 Dec;251(12):2705-9. PMID: 23689994.
Xiang T, Jia Y, Sherris D, et al. Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene. 2011 May 26;30(21):2443-50. PMID: 21242970.
Xue Q, Hopkins B, Perruzzi C, et al. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res. 2008 Nov 15;68(22):9551-7. PMID: 19010932.
